NCT03301220 2026-03-18A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple MyelomaJanssen Research & Development, LLCPhase 3 Active not recruiting390 enrolled 12 charts 1 FDA